Novo Nordisk EVOKE plus NN6535-4725 (Phase 3a)

Back to Drug Development Trials
Drug Development Trials

About the trial

This phase 3 study aims to determine the safety and the impact of oral Semaglutide on the cognitive function in subjects with MCI (mild cognitive impairment) or mild Alzheimer’s disease. Semaglutide, sold under the brand names of Ozempic and Rybelsus, is GLP-1 receptor agonist used for the treatment of type 2 diabetes. Recent clinical data has shown that Semaglutide reduces the risk of dementia by lowering neuro inflammation. It is administered by oral tablet once a day.